Who gets to take part in the next chapter of dementia research?

Alzheimer’s Disease International released its World Alzheimer Report 2026 on 21 September, examining how dementia clinical trials can become more accessible, representative and effective. Co-authored with journalist Paul Gallagher, the report combines evidence with accounts from people involved in research.

Recruitment is a central concern. Dementia Researcher’s analysis of the report cites 158 therapies in 192 active Alzheimer’s trials, with nearly 55,000 participant places to fill. Those figures describe research activity, not treatments proven to work.

The report examines barriers throughout a trial: finding suitable participants, supporting their continued involvement, addressing safety and ethics, and ensuring that different parts of the world are represented. It also identifies a need to improve clinicians’ awareness and understanding of research opportunities.

Alongside explanations of how trials operate, the publication includes personal perspectives on taking part. Its recommendations address both scientific progress and the conditions needed to make participation possible. ADI has made the English-language report available as a free digital download.

Sources:

• Alzheimer’s Disease International — World Alzheimer Report 2026

• Dementia Researcher — World Alzheimer Report 2026: Key Findings